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Abstract
We report a case of a 54-year-old patient who was 
denied surgical replacement for severe aortic stenosis 
because of complicated acquired immunodeficiency 
syndrome and who successfully underwent transcath-
eter aortic valve implantation at our institution.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: The present case report describes the feasibil-
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INTRODUCTION
The transcatheter aortic valve implantation (TAVI) proce-
dure is currently considered a valid alternative to surgery 
in patients with severe aortic stenosis not eligible for 
valve replacement or with high operative risk, as demon-
strated by the recent PARTNER[1] trial, which showed 
similar results between surgery and TAVI. For this rea-
son, it may represent an attractive option for patients 
whose surgical risk is difficult to assess, like immuno-
compromised ones.
CASE REPORT
We report the case of  a 54-year-old male (82 kg, 178 
cm) with a diagnosis of  post-transfusion HIV infection 
in 1990, who had taken six different antiretroviral drugs 
because of  a virus with several resistances. In October 
2009, the patient was hospitalized for Listeria meningitis 
and he suffered from several episodes of  acute heart fail-
ure, after which severe aortic stenosis was diagnosed by 
transthoracic echocardiography (TTE), with a mean gra-
dient of  55 mmHg and an ejection fraction of  50% with-
out coronary disease at the angiography. The patient was 
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consequently referred to cardiac surgeons who refused to 
do the procedure due to a high operative risk, with a Cd4 
cell count of  400 cell/cc and low count of  platelets. Nev-
ertheless, from December 2010 he became symptomatic 
(NYHA Ⅲ) and had several syncopal episodes, the last 
of  which led to a leg fracture.
The patient was referred again to our surgeons who 
considered him for TAVI, despite his age and low risk 
detected by common scores (Logistic EuroSCORE 
1.51%, STS 3%). Multidisciplinary discussion, including 
the infectious diseases specialist who foresaw at least a 
2-year survival and a high risk of  potential life threaten-
ing peri-intervention infections at the same time, led to 
the decision of  a percutaneous transfemoral approach 
to minimize all potential sites of  infection, both for the 
patient and the operators. He was successfully treated 
with a 29 mm CoreValve and discharged uneventfully on 
post-operative day nine (Figure 1). His TTE showed a 
mean gradient of  12 mmHg and mild paraprothesic aor-
tic insufficiency. His cardiovascular therapy consisted of  
aspirin, clopidogrel and furosemide 25 mg.
Two weeks after discharge, he presented to the emer-
gency department because of  angina (CCS Ⅱ) and re-
peated episodes of  gingival bleeding and melena. ECG 
was unchanged but important anemia (Hb 8 g/dL) was 
detected, so clopidogrel was stopped.
At the 12 mo follow-up, he was in NYHA Ⅰ and had no 
further syncope or angina. Ejection fraction was 51%, with 
a mean transprothesic gradient of  12 mmHg and still mild 
paraprothesic aortic insufficiency on echocardiography.
DISCUSSION
The numbers of  immunocompromised patients with 
aortic stenosis will increase because of  longer survival for 
HIV patients[2-4].
Despite some encouraging reports from patients with 
uncomplicated HIV[5], their management can be really 
tricky: for patients, because of  a high infective risk, high 
prevalence of  renal disease and consequently a risk of  
bleeding or thrombosis[4-6], and for surgeons, due to con-
tamination risk[7]. Moreover, accurate tools to correctly as-
sess risk in immunocompromised patients (not appraised 
by EuroSCORE and only partially by the STS score[8,9]) 
are lacking and no data are reported about in hospital and 
midterm follow up complications. This medical issue will 
become more and more relevant due to the increase in 
survival of  patients with immunodeficiency (both HIV 
or after transplant). It must be remembered that in some 
countries, such as the United States, the TAVI procedure 
is still considered to be in an initial phase and this can 
affect the lack of  data regarding this population. To the 
best of  our knowledge, this is the first HIV patient with 
severe aortic stenosis treated by TAVI, which was chosen 
mainly due to the infective risk. TAVI, with an accurate 
treatment of  in-hospital complications, may represent a 
feasible choice for those with HIV/AIDS.
COMMENTS
Case characteristics
Aggressive acquired immunodeficiency syndrome (AIDS) in a patient referred 
for invasive cardiac surgery to improve his life expectancy.
Clinical diagnosis
NYHA Ⅲ: reduced second heart sound with systolic murmur heard. Electrocar-
diogram (ECG) with left ventricle hypertrophy and echocardiogram confirming 
severe stenosis.
Differential diagnosis
After syncope, ECG monitoring did not show any atrioventricular block.
Laboratory diagnosis
The lymphocyte typing detected a significant reduction in the lymphocyte sub-
population of CD3+, CD4+ and CD19+.
Imaging diagnosis
Transthoracic echocardiography showed the left ventricle with concentric hy-
pertrophy and FE of 55%; severe aortic stenosis with AVA 0.8 cm² and mean 
transvalvular gradient of 55 mmHg without coronary disease at angiography.
Pathological diagnosis
HIV-positive patient treated with anti-retroviral therapy, suffering from symptom-
atic severe aortic stenosis.
Treatment
Transfemoral transcatheter aortic valve implantation (TAVI).
Term explanation
Core Valve is a valve prosthesis, comprised of 3 porcine pericardial tissue leaf-
lets mounted in a self-expanding nitinol frame. This valve has only been used 
in a retrograde approach, either via transfemoral, subclavian or direct aortic 
access.
Experiences and lessons
TAVI can be considered a therapeutic option for severe aortic stenosis in a 
severe immunosuppressed status, as for patients with AIDS treated with antiret-
roviral therapy.
Peer review
The argument could be considered a strong point because in the literature, this 
is not treated; in fact, this was the first TAVI procedure on a patient affected by 
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Figure 1  Positioning image. A: Pig tail positioning before transcatheter aortic 
valve implantation; B: Valve after positioning.
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B
 COMMENTS
AIDS at high risk for valve surgical replacement. So, this case report represents 
an example for an alternative therapeutic option, giving an opportunity for these 
patients to be cured despite their important comorbidity.
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